BidaskClub lowered shares of Dynavax Technologies (NASDAQ:DVAX) from a hold rating to a sell rating in a research note released on Tuesday morning.

Several other equities analysts also recently weighed in on the stock. Cantor Fitzgerald reaffirmed a buy rating and set a $30.00 price target on shares of Dynavax Technologies in a report on Monday, October 1st. ValuEngine raised shares of Dynavax Technologies from a sell rating to a hold rating in a report on Tuesday, October 23rd. Cowen reaffirmed a buy rating and set a $30.00 price target on shares of Dynavax Technologies in a report on Monday, October 22nd. Zacks Investment Research raised shares of Dynavax Technologies from a sell rating to a hold rating in a report on Thursday, August 9th. Finally, Royal Bank of Canada lifted their price target on shares of Dynavax Technologies to $26.00 and gave the company an outperform rating in a report on Monday, October 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Dynavax Technologies has an average rating of Hold and a consensus price target of $28.00.

Shares of NASDAQ:DVAX opened at $10.70 on Tuesday. The company has a current ratio of 6.29, a quick ratio of 5.90 and a debt-to-equity ratio of 1.03. Dynavax Technologies has a 1-year low of $9.63 and a 1-year high of $22.80. The company has a market cap of $664.53 million, a price-to-earnings ratio of -6.18 and a beta of 0.46.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Dynavax Technologies had a negative net margin of 5,044.85% and a negative return on equity of 97.79%. The firm had revenue of $1.46 million for the quarter, compared to analysts’ expectations of $3.16 million. During the same period in the prior year, the firm earned ($0.38) EPS. Dynavax Technologies’s revenue for the quarter was up 2822.0% compared to the same quarter last year. On average, equities research analysts predict that Dynavax Technologies will post -2.51 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new stake in shares of Dynavax Technologies during the third quarter valued at approximately $131,000. Pacer Advisors Inc. bought a new stake in shares of Dynavax Technologies during the third quarter valued at approximately $132,000. Gofen & Glossberg LLC IL bought a new stake in shares of Dynavax Technologies during the third quarter valued at approximately $145,000. Tiverton Asset Management LLC bought a new stake in shares of Dynavax Technologies during the second quarter valued at approximately $184,000. Finally, Bank of Montreal Can raised its position in shares of Dynavax Technologies by 365.4% during the second quarter. Bank of Montreal Can now owns 13,938 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 10,943 shares during the last quarter. Hedge funds and other institutional investors own 76.73% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Further Reading: Should you buy a closed-end mutual fund?

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.